Assistive devices with built-in locking mechanisms
The auxiliary device for drug delivery systems addresses user-friendliness and compliance issues by allowing indirect manipulation and electronic control, ensuring accurate dose setting and preventing misuse, thus enhancing safety and adherence to prescription schedules.
Patent Information
- Application Number
- JP2024526566
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-03
- Filing Date
- 2022-11-01
- Publication Date
- 2024-11-13
AI Technical Summary
Existing drug delivery devices, particularly for patients with chronic diseases like diabetes, face challenges in being user-friendly, easy to operate, and ensuring accurate dose setting and dispensing, especially for those with impaired vision or physical frailty, while also preventing misuse and ensuring compliance with prescription schedules.
An auxiliary device is designed to be removably attached to a drug delivery device, featuring a fastener and control element that allows for indirect manipulation of the device components, with an electronic unit and locking mechanism to ensure proper operation and compliance with prescription schedules, using authentication and coding features to prevent misuse.
The auxiliary device enhances user safety and compliance by enabling easy and accurate dose setting and dispensing, while preventing improper use and ensuring that only authorized and prescribed medications are administered.
Smart Images

Figure 2024542089000001_ABST
Abstract
Description
[Technical field]
[0001] The present disclosure relates to an auxiliary device for use with a drug delivery device.The present disclosure further relates to a drug delivery system. [Background technology]
[0002] Drug delivery devices for setting and dispensing single or multiple doses of liquid medicaments are known per se in the art. In general, such devices have substantially the same purpose as a conventional syringe.
[0003] Drug delivery devices, e.g., injection devices and needle-based injection system (NIS) devices such as pen-type injectors, must meet multiple user-specific requirements. For example, for patients suffering from chronic diseases such as diabetes, the patient may be physically frail and have poor eyesight. Therefore, a suitable drug delivery device, especially intended for home medicines, must be of robust construction and must be easy to use. Furthermore, the operation and general handling of the device and its parts must be straightforward and easily understandable. Such an injection device should provide for the setting and subsequent dispensing of variable-sized drug doses. Furthermore, the dose setting as well as the dose dispensing procedure must be easy to operate and clear.
[0004] A patient suffering from a particular disease may require a certain amount of medication to be injected via a syringe pen or infused by a pump.
[0005] Some drug delivery or injection devices allow for the selection of variable sized drug doses and inject a preset dose. Some injection devices allow for the setting and dispensing of a fixed dose, where the amount of drug that must be injected according to a predefined prescription schedule is always the same and does not or must not change over time.
[0006] Some injection devices are realized as reusable injection devices, where the drug container, such as a cartridge, can be replaced by the user. Other injection devices are realized as disposable injection devices, where the intention is to discard the entire injection device once the contents, i.e. the drug, have been used up.
[0007] In a reusable injection device, the drug fluid container, i.e. the cartridge, must be replaced when the drug runs out. Here, the drug container, e.g. a glass cartridge filled with the drug fluid, must be replaced. Some primary drug containers, e.g. in the form of a cartridge filled with the drug, are preassembled in a housing part of the injection device, such as a cartridge holder.
[0008] For example, there are further electronic units, also indicated as auxiliary or add-on devices, integrated into such delivery or injection devices or provided as separate devices. Such auxiliary devices provide additional functionality to the all-mechanically realized drug delivery or injection devices. By means of the auxiliary devices, the setting of drug doses and the repetition of dosing or injection can be precisely monitored and recorded over time. The auxiliary devices provide a wide variety of auxiliary functions for the regular use of the drug delivery or injection devices. The auxiliary devices can perform data analysis and further transmission of such data to the healthcare provider. Such data is indicative of the amount of drug administered at a particular time or on a particular date.
[0009] Electronically implemented auxiliary devices, for example detachable and mechanically connectable to the drug delivery device or injection device, can facilitate the handling and operation of such drug delivery devices. Summary of the Invention [Problem to be solved by the invention]
[0010] In view of the above, it is a further object to enhance patient safety, to improve the range of functionality of such auxiliary devices, drug delivery devices for use with such auxiliary devices, and to provide an improved injection system including a drug delivery device and an auxiliary device. [Means for solving the problem]
[0011] In one aspect, an auxiliary device is provided for attachment to a drug delivery device. The drug delivery device is operable to set and dispense a drug dose. Typically, the drug delivery device is realized as an injection device, such as a hand-held injection device. The drug delivery device may constitute a pen-type injector. The auxiliary device is provided as a separate device that can be removably coupled to the drug delivery device. The auxiliary device, also denoted as an add-on device, provides additional functionality to the drug delivery device and aims to extend the functional range of the drug delivery device.
[0012] The auxiliary device includes a fastener configured to fasten to a first component of the drug delivery device. The auxiliary device further includes a control element configured to engage with a second component of the drug delivery device. The control element typically engages or is engagable with the second component of the drug delivery device when the auxiliary device is properly attached, e.g., mechanically fastened, to the first component of the drug delivery device.
[0013] The control element is movable relative to the fastener to guide movement of the second component of the drug delivery device relative to the first component of the drug delivery device when the fastener is attached to the first component. In effect, the first and second components of the drug delivery device are movable relative to each other, for example, for setting a drug dose and / or dispensing or injecting a drug dose.
[0014] Similarly, the fastener and the control element of the auxiliary device are movable relative to each other, just as the first and second components of the drug delivery device are movable relative to each other. If the first and second components of the drug delivery device are movable, for example, along the longitudinal direction, the control element is also movable relative to the fastener along the longitudinal direction. If the first and second components of the drug delivery device are rotatable relative to each other, the fastener may also be rotatable relative to the control element.
[0015] Typically, when the auxiliary device is properly attached to the drug delivery device, at least one of the fastener and the control element can cover and / or surround at least one of the first component of the drug delivery device and the second component of the drug delivery device. Here, the attachment of the auxiliary device to the drug delivery device may inhibit or prevent direct access to at least one of the first and second components of the drug delivery device. For example, if the fastener of the auxiliary device is rigidly attached or fixed to the first component of the drug delivery device, the manual operation or manual guided movement of the auxiliary device relative to the drug delivery device, and thus the fastener of the auxiliary device relative to the drug delivery device, can cause the movement of the first component of the drug delivery device, for example, relative to the housing of the drug delivery device.
[0016] When properly attached to the drug delivery device, the control element of the auxiliary device can cover and / or mechanically engage the second component of the drug delivery device. Manually inducing the movement or motion of the control element relative to the fastener then induces the movement of each of the second device parts relative to the first device part. In this way, when the auxiliary device covers or surrounds at least one of the first and second components of the drug delivery device, it can provide indirect movement or manipulation of at least one of the first and second components of the drug delivery device through the engagement of the control element with the second component via the movability of the control element relative to the fastener, via the engagement of the fastener with the first component, respectively.
[0017] The auxiliary device further includes an electronic unit, the electronic unit including at least a processor. The auxiliary device further includes a locking mechanism, the locking mechanism including an electromechanical actuator, the electromechanical actuator controllable by the processor and operable to block or inhibit movement of the control element relative to the fastener.
[0018] Typically, the locking mechanism is transitionable between a release configuration and a locking configuration. In the release configuration, the locking mechanism allows and supports the movement of the control element relative to the fastener, for example, to induce the movement of the second component of the drug delivery device relative to the first component of the drug delivery device. When in the locking configuration and as long as it is in the locking configuration, the locking mechanism blocks or inhibits at least one-way movement of the control element relative to the fastener. In this way, if the user has to try to induce the movement of the second component of the drug delivery device relative to the first component of the drug delivery device, for example by moving, for example by pushing, the control element relative to the fastener, the respective movement is blocked and prevented as long as the locking mechanism is in the locking configuration. The user is then unable to induce the respective movement of the second component of the drug delivery device.
[0019] Here, activation of the locking mechanism by the electromechanical actuator and / or the processor that actually controls the electromechanical actuator prevents respective movement of the control element relative to the fastener.
[0020] In a further aspect, the auxiliary device itself may comprise an electrically or electronically implemented authentication function or arrangement, which may electronically control authorized access to the auxiliary device, and thus to the drive unit, and thus the auxiliary device may effectuate the transition of the locking element to the released position or configuration only if a user attempting to use the drive unit or drug delivery device passes an authentication procedure by the auxiliary device.
[0021] Additionally, the auxiliary device can be configured to automatically lock. The auxiliary device can include a timed lock. In some examples, the auxiliary device can include patient-specific data indicating, for example, the amount of medication and / or the time or date the injection is scheduled. Because the auxiliary device is configured to unlock the locking mechanism only if the user's use of the drug delivery device is consistent with a predetermined prescription or dosing schedule, a user attempting to use the drive unit at other times to administer an improperly sized dose is effectively prevented from doing so.
[0022] In a further example, the authentication function performed by the auxiliary device may be operable to distinguish between different container units, e.g. container units comprising different drug containers or medicaments. Here, the drug delivery device, in particular its drive unit, is configured to engage with several different configurations of container units, e.g. differing amounts, concentrations and / or types of drugs or medicaments. Each of the container units, which are generally attachable to the drive unit, may be provided with a unique identifier, e.g. by means of an electrically detectable or visual code or coding feature. Here, the auxiliary device may be operable to read or extract the relevant code information in order to obtain respective information regarding the drugs or medicaments provided in the container units.
[0023] The container unit comprising the drug container is visually or electronically encoded by a respective coding feature, implemented for example as a barcode, as a QR code or in the form of an electronically readable code, for example provided by an RFID chip. The auxiliary device and / or an external electronic device operable to communicate with the auxiliary device may be operable to capture and / or read or extract the coding feature of the container unit. Based on the captured coding feature, at least one of the auxiliary device and the external electronic device may evaluate the coding feature. The evaluation of the coding feature may include, for example, a comparison of the coding feature with user-specific information stored in one of the auxiliary device and the external electronic device. If the coding feature matches the user-specific information, for example if it should be determined that the type of drug located in the container unit matches the prescription schedule of a particular user, the locking mechanism should be transitioned to a release configuration to enable and assist administration of the drug dose.
[0024] In other cases, if the type of medication should be determined to be inconsistent with, for example, a particular user's predetermined prescription schedule, the electronic unit, and thus its processor, can be operable to maintain the locking mechanism in a locked configuration to protect the patient from administration of medication inconsistent with the prescription schedule. In this manner, misuse or unintended use of the drive unit can be effectively prevented.
[0025] According to a further example, the control element is movable relative to the fastener along the longitudinal direction between an idle position and an activation position. In some examples, the drug delivery device is elongated in shape. The drug delivery device can extend along the longitudinal direction. Here, the auxiliary device is configured to be attached to a longitudinal end of the drug delivery device, typically a proximal end of the drug delivery device where the first and second components of the drug delivery device are located. Typically, the distal end of the drug delivery device is configured to eject or inject a drug dose. When in the idle position, the control element may be mechanically engaged, e.g., mechanically abutting, with the second component of the drug delivery device.
[0026] Movement of the control element relative to the fastener, e.g., distal movement of the control element relative to the fastener, can induce distal movement of a second component of the drug delivery device relative to the first component of the drug delivery device. In some examples, the control element is pushed distally relative to the fastener, thereby exerting a corresponding pushing action on the second component. Pushing the second component distally relative to the first component can induce or trigger a dosing or injection procedure performed by the drug delivery device.
[0027] According to a further example, the control element includes a first sidewall section. The fastener includes a second sidewall section. The first sidewall section is in longitudinal sliding engagement with the second sidewall section. In this manner, the first and second sidewall sections can provide a sliding guide for providing controlled sliding displacement of the control element relative to the fastener.
[0028] In other examples, the first and second sidewall sections can enable or support rotational movement of the control element relative to the fastener, where the first sidewall section can define a tubular structure and the second sidewall section can define a complementary shaped tubular structure.
[0029] In any event, at least one of the first and second sidewall sections includes an outwardly facing surface that slidably engages an inwardly facing surface of the other of the first and second sidewall sections. In this manner, the first and second sidewall sections are arranged in a somewhat alternating or nested manner. Thus, the control element can move telescopically relative to the fastener. The sliding engagement of the first and second sidewall sections provides precise, guided movement of the control element relative to the fastener.
[0030] According to a further example, the locking mechanism includes a locking element mechanically coupled to an electromechanical actuator. The locking element is movable between a locked position and a released position by the electromechanical actuator. A movement of the locking element or a respective configuration of the locking element can define an operating state of the locking mechanism. Thus, when the locking element is in the locked position, the locking mechanism is in the locked configuration. When the locking element is in the released position, the locking mechanism is in the released configuration.
[0031] The electromechanical actuator may include an electromechanical drive, an electromagnet, or the like, to induce at least one of a bending, movement, or pivoting of the locking element induced by an electric current controlled by the electronic unit and its processor.
[0032] In a further example, the locking element is movably disposed on one of the fastener and the control element. When the locking element is in a locked position, the locking element is mechanically engageable with the other of the fastener and the control element. Typically, the locking element is provided on one of the first and second sidewall sections and may be operable, for example, to selectively engage with the other of the first and second sidewall sections. The engagement of the locking element with at least one of the fastener and the control element may include one of a positive fit and a friction fit. Movement of the locking element from the locked position to the released position may disable the respective positive fit or friction fit.
[0033] In other examples, the locking element can be provided on another component of the auxiliary device, e.g., the other component is secured to one of the fastener and the control element, and can then be transitioned to a release position to mechanically interact with or mechanically lock to one of the fastener and the control element.
[0034] In a further example of the auxiliary device, the locking element is movable along a radial or lateral direction between a locking position and a release position. In a further example, the locking element is deformable along a radial direction and can adopt at least one of a locking shape and a release shape. When in the locking shape, the locking element is in a locking configuration or a locking position. When in the release shape, the locking element is in a release configuration or a release position.
[0035] In some examples, the locking element may be elastically deformable. In an unbiased or idle position or configuration, the locking element may be in one of a locked position and a released position. By inducing mechanical deformation of the locking element, it may be transitioned or deformed toward the other of the locked position and the released position. In either case, the locking element may also be radially or laterally movable and / or deformable so as to selectively engage at least one of a radial recess or a radial protrusion to block or inhibit movement of the control element relative to the fastener.
[0036] According to another example, the locking element is configured to protrude radially from one of the first and second sidewall sections. The locking element is further operable or configured to engage a radial recess or engage a longitudinal end surface of the other of the first and second sidewall sections. Typically, the locking element can be disposed at an interface between the first and second sidewall sections. By moving the locking element radially or laterally, the locking element can protrude from one of the inner-facing and outer-facing surfaces of one of the first and second sidewall sections. The locking element can then engage the other of the inner-facing and outer-facing surfaces of the other of the first and second sidewall sections.
[0037] In this manner, when the locking element, for example formed as a radial protrusion, engages with the radial recess, a positive fit or form-fitting engagement is provided between the first and second sidewall sections, and thus between the fastener and the control element. As long as the protruding locking element is engaged with the radial recess, further movement of the control element relative to the fastener is effectively prevented.
[0038] In another example, the movable locking element can include a radial recess and be configured to engage a complementarily shaped protrusion, where the locking element can be radially movable in one of the first and second sidewall sections such that it can engage a protrusion provided in the other of the first and second sidewall sections.
[0039] According to a further example, the locking mechanism is mechanically coupled to the electromechanical actuator by means of a movable piston. The movable piston may constitute an elongated shaft. The elongated shaft may extend substantially along a radial or lateral direction. Thus, actuation of the electromechanical actuator may induce a radial movement of the movable piston and thus a radial or lateral movement of each of the locking elements. The locking elements are provided or fixed to longitudinal ends of the movable piston.
[0040] According to a further example, the locking element is rotatable or pivotable about an axis extending along the longitudinal direction. The pivoting or rotation of the locking element is also induced by an electromechanical actuator. Here, the electromechanical actuator may be operable to rotate the axis or a shaft overlapping the axis. The locking element is attached to or mechanically coupled with the electromechanical actuator via the axis or shaft. Here, the electromechanical actuator may include a step motor to precisely angularly rotate the locking element.
[0041] According to a further example, the locking element includes a locking disc having a keyed structure extending around a circumference of the locking disc. The locking disc may be circular or annular in shape. In another example, the locking disc may include a radially outwardly extending flange connected to an axle or shaft.
[0042] The keyed structure is configured and shaped to engage a complementary shaped corresponding keyed structure. Typically, a locking element, e.g., a locking disk, is longitudinally fixed to one of the fastener and the control element. A corresponding keyed structure is provided on the other of the fastener and the control element. The plane of the locking disk can extend longitudinally and / or radially or transversely to the axis of rotation of the rotatable locking element.
[0043] Thus, longitudinal sliding movement of the keyed structure of the locking disc relative to the corresponding keyed structure is supported and effective only when the keyed structure is correctly aligned with the corresponding keyed structure in a longitudinal direction. In any other orientation or rotational state of the locking disc, longitudinal displacement of the locking disc, and thus of each of the locking elements, is effectively prevented.
[0044] In a further example, the locking element is disposed on one of the control element and the fastener. The other of the control element and the fastener includes a receptacle having a corresponding keyed structure that is complementary in shape to the structure of the locking element. Movement of the locking element into the receptacle is possible and permitted only when the keyed structure is properly aligned or flush with the corresponding keyed structure. In any other orientation, the keyed structure will not match the corresponding keyed structure and may thus inhibit or prevent insertion of the locking element into the receptacle. In this way, longitudinal sliding movement of the control element relative to the fastener is effectively inhibited and prevented.
[0045] According to a further example of the auxiliary device, the locking disc is positioned longitudinally offset from the corresponding keyed structure when the control element is in the idle position such that the locking disc is operable to prevent longitudinal movement of the control element relative to the fastener due to the keyed structure being offset relative to the corresponding keyed structure.
[0046] Thus, in a further example, the control element is movable relative to the fastener towards the actuated position only when the keyed structure of the locking disc is aligned with a corresponding keyed structure of the receptacle.
[0047] In some examples, the keyed structure is provided on an outwardly facing surface of the locking disc. The keyed structure is located on the outer edge or periphery of the locking disc. The diameter or inner cross section of the receptacle may be of a shape complementary to the geometrical structure of the keyed structure of the locking disc. In some examples, the keyed structure includes at least one radial protrusion and / or at least one radial recess. The corresponding keyed structure constitutes a structure of a complementary shape formed by at least one of the radial protrusion and the radial recess. Typically, the keyed structure includes a protrusion configured to engage with a respective recess provided by the corresponding keyed structure. The corresponding keyed structure may include several elongated slots with a continuous profile along the longitudinal direction. This allows longitudinal sliding movement of the keyed structure relative to the corresponding keyed structure.
[0048] In some examples, the keyed structure includes a series of teeth and recesses viewed along the circumference of the locking disk, and the corresponding keyed structure of the receptacle accordingly includes a respective series of corresponding teeth and corresponding recesses.
[0049] The electronic unit, in particular its processor and electromechanical actuator, is configured and operable to align the keyed structure with the corresponding keyed structure or to misalign the keyed structure relative to the corresponding keyed structure. In a misaligned configuration, the keyed structure is prevented from longitudinally entering the recess. Only in a properly aligned configuration, where the keyed structure is longitudinally flush with the corresponding keyed structure, is it possible to longitudinally displace the keyed structure into the recess, which action is accompanied by a respective sliding action of the control element relative to the fastener.
[0050] In another aspect, the present disclosure further relates to a drug delivery system. The drug delivery system includes the above auxiliary device. The drug delivery system further includes a drug delivery device. The drug delivery device is realized as an injection device, for example, as a hand-held pen-type injector. The drug delivery system can then include or constitute a drug injection system. The drug delivery device can be configured or operable to set and / or dispense a drug dose.
[0051] The drug delivery device includes a container unit configured to accommodate a drug container. The drug delivery device further includes a drive unit operably engageable with the drug container to set and dispense a drug dose. The drug delivery device further includes at least one of a dose dial for setting the dose and a trigger for dispensing the dose. In some examples where the drug delivery device includes a dose dial and a trigger provided as separate components movable relative to each other, the fastener of the auxiliary device may be configured to secure or fasten to the dose dial and the control element may be operable to mechanically engage with the trigger.
[0052] Thereby, and in another example of guiding a drug delivery operation, when the auxiliary device is attached to the dose dial of the drug delivery device, the control element may be displaceable in the longitudinal direction relative to the fastener such that user-guided movement of the control element in the distal direction relative to the fastener can then induce a respective displacement of the trigger relative to the dose dial.
[0053] In other examples, where the drug delivery device includes only one user operable component, e.g., a dose dial and a trigger integrated into one mechanical component, e.g., designated as the dosing element, the fastener of the auxiliary device may be configured to fasten to the housing or housing part of the drug delivery device, whereas the control element may be configured to engage or fasten to the dosing element, the control element being torque proof engaged with the dosing element and rotatable relative to the fastener, thereby being able to guide rotation of the dosing element relative to the housing or housing part when the auxiliary device is properly secured to the drug delivery device.
[0054] The control element may also be longitudinally displaceable relative to the fastener, for example to guide distal displacement or movement of each of the administration elements relative to the housing of the drug delivery device, thereby triggering a dosing or injection operation.
[0055] The locking mechanism may be operable to lock at least one of rotational movement of the control element relative to the fastener and longitudinal movement of the control element relative to the fastener.
[0056] In a further example, the drug delivery device also comprises a medicament container, e.g. realised as a cartridge, arranged in the container unit. Typically, the drive unit of the drug delivery device comprises a piston rod which biases a bung or stopper movably arranged in or on the medicament container, e.g. to expel the medicament from a distal outlet of the medicament container.
[0057] The drive unit of the drug delivery device may be fully mechanically realised, where the force to exert or withdraw the drug dose from the drug container may have to be fully provided by the user of the device.
[0058] In general, the scope of the present disclosure is defined by the content of the claims. The injection device is not limited to a particular embodiment or example, but includes any combination of elements of different embodiments or examples. To that extent, the present disclosure covers any combination of the claims and any technically feasible combination of the features disclosed in relation to the different examples or embodiments.
[0059] It will be further apparent to those skilled in the art that various modifications and variations can be made to the present disclosure without departing from the scope of the present disclosure. Furthermore, it should be noted that any reference numerals used in the appended claims should not be construed as limiting the scope of the present disclosure.
[0060] As used herein, the term "distal" or "distal end" refers to the end of a drug delivery or injection device that faces towards the injection site of a human or animal. The term "proximal" or "proximal end" refers to the opposite end of an injection device that faces away from the injection site of a human or animal.
[0061] The terms "drug" or "medicament" are used interchangeably herein to describe a pharmaceutical formulation containing one or more active pharmaceutical ingredients or their pharma- ceutically acceptable salts or solvates, and optionally a pharma- ceutically acceptable carrier. An active pharmaceutical ingredient ("API"), in its broadest sense, is a chemical structure that has a biological effect on humans or animals. In pharmacology, drugs or medicines are used to treat, cure, prevent, or diagnose diseases or otherwise improve physical or mental well-being. Drugs or medicines can be used for a limited duration or periodically for chronic disorders.
[0062] As described below, a drug or agent may include at least one API or a combination thereof in various types of formulations for the treatment of one or more diseases. Examples of APIs may include small molecules with molecular weights of 500 Da or less, polypeptides, peptides, and proteins (e.g., hormones, growth factors, antibodies, antibody fragments, and enzymes), carbohydrates and polysaccharides, as well as nucleic acids, double-stranded or single-stranded DNA (including naked and cDNA), RNA, antisense nucleic acids such as antisense DNA and RNA, small interfering RNA (siRNA), ribozymes, genes, and oligonucleotides. Nucleic acids may be incorporated into molecular delivery systems such as vectors, plasmids, or liposomes. Mixtures of one or more drugs are also contemplated.
[0063] The drug or agent can be contained in a primary package or "drug container" adapted for use in a drug delivery device. The drug container can be, for example, a cartridge, syringe, reservoir, or other rigid or flexible vessel configured to provide a chamber suitable for storage (e.g., short-term or long-term storage) of one or more drugs. For example, in some cases, the chamber can be designed to store the drug for at least one day (e.g., from one day to at least 30 days). In some cases, the chamber can be designed to store the drug for about one month to about two years. Storage can be at room temperature (e.g., about 20°C) or at refrigerated temperatures (e.g., from about -4°C to about 4°C). In some cases, the drug container can be or include a dual-chamber cartridge configured to separately store two or more components of a pharmaceutical formulation to be administered (e.g., an API and a diluent, or two different drugs), one in each chamber. In such cases, the two chambers of the dual-chamber cartridge can be configured to allow mixing between the two or more components before and / or during administration to the human or animal body. For example, the two chambers can be configured to be in fluid communication with each other (e.g., via a conduit between the two chambers) and to optionally allow mixing of the two components by a user prior to administration. Alternatively or additionally, the two chambers can be configured to allow mixing upon administration of the components to the human or animal body.
[0064] The drugs or agents contained in the drug delivery devices described herein can be used for the treatment and / or prevention of many different types of medical disorders. Examples of disorders include, for example, diabetes or complications associated with diabetes, such as diabetic retinopathy, thromboembolic disorders, such as deep vein thromboembolism or pulmonary thromboembolism. Further examples of disorders are acute coronary syndromes (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and / or rheumatoid arthritis. Examples of APIs and drugs are those found in handbooks such as Rote Liste 2014 (e.g., but not limited to, Main Groups 12 (antidiabetic agents) or 86 (oncology agents)) and the Merck Index, 15th edition.
[0065] Examples of APIs for the treatment and / or prevention of type 1 or type 2 diabetes or complications associated with type 1 or type 2 diabetes include insulin, e.g., human insulin, or a human insulin analog or derivative, glucagon-like peptide (GLP-1), a GLP-1 analog or GLP-1 receptor agonist, analog or derivative thereof, a dipeptidyl peptidase-4 (DPP4) inhibitor, or a pharma-ceutically acceptable salt or solvate thereof, or any mixture thereof. As used herein, the terms "analog" and "derivative" refer to a polypeptide having a molecular structure that is formally derivable from the structure of a naturally occurring peptide, e.g., the structure of human insulin, by deletion and / or replacement of at least one amino acid residue present in the naturally occurring peptide and / or by addition of at least one amino acid residue. The added and / or replaced amino acid residues can be either codable amino acid residues or other naturally occurring residues or purely synthetic amino acid residues. Insulin analogs are also referred to as "insulin receptor ligands". In particular, the term "derivative" refers to a polypeptide having a molecular structure formally derivable from the structure of a naturally occurring peptide, for example the molecular structure of human insulin in which one or more organic substituents (e.g., fatty acids) are attached to one or more of the amino acids. Optionally, one or more amino acids present in the naturally occurring peptide are deleted and / or replaced by other amino acids, including non-codeable amino acids, or amino acids, including non-codeable ones, are added to the naturally occurring peptide.
[0066] Examples of insulin analogues are Gly(A21), Arg(B31), Arg(B32) human insulin (insulin glargine); Lys(B3), Glu(B29) human insulin (insulin glulisine); Lys(B28), Pro(B29) human insulin (insulin lispro); Asp(B28) human insulin (insulin aspart); human insulin in which the proline in position B28 may be replaced by Asp, Lys, Leu, Val or Ala and in which the Lys in position B29 may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.
[0067] Examples of insulin derivatives are e.g. B29-N-myristoyl-des(B30) human insulin, Lys(B29)(N-tetradecanoyl)-des(B30) human insulin (insulin detemir, Levemir®); B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin. ; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-gamma-glutamyl)-des(B30) human insulin, B29-N-omega-carboxypentadecanoyl-gamma-L-glutamyl-des(B30) human insulin (insulin degludec, Tresiba®); B29-N-(N-lithocholyl-gamma-glutamyl)-des(B30) human insulin; B29-N-(ω-carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(ω-carboxyheptadecanoyl) human insulin.
[0068] Examples of GLP-1, GLP-1 analogs and GLP-1 receptor agonists are, for example, lixisenatide (Lyxumia®), exenatide (exendin-4, Byetta®, Bydureon®, a 39 amino acid peptide produced by the salivary glands of the flathead monster), liraglutide (Victoza®), semaglutide, taspoglutide, albiglutide (Syncria®), dulaglutide (Trulicity®), rExendin-4, CJC-1134-PC, PB-1023, TTP-054, langrenatide / HM-11260C (efpegrenatide). , HM-15211, CM-3, GLP-1 Erigen, ORMD-0901, NN-9423, NN-9709, NN-9924, NN-9926, NN-9927, Nodexene, Viador-GLP-1, CVX-096, ZYOG-1, ZYD-1, GSK-2374697, DA-3091, MAR-701, MAR709, ZP-2929, ZP-3022, ZP -DI-70, TT-401 (Pegapamodtide), BHM-034, MOD-6030, CAM-2036, DA-15864, ARI-2651, ARI-2255, Tirzepatide (LY3298176), Bamadutide (SAR425899), Exenatide-XTEN and Glucagon-Xten.
[0069] Examples of oligonucleotides are, for example, the cholesterol-lowering antisense therapeutic mipomersen sodium (Kynamro®) for the treatment of familial hypercholesterolemia, or RG012 for the treatment of Alport Syndrome.
[0070] Examples of DPP4 inhibitors are linagliptin, vidagliptin, sitagliptin, denagliptin, saxagliptin, berberine.
[0071] Examples of hormones include pituitary or hypothalamic hormones or regulatory active peptides and their antagonists, such as gonadotropins (follitropin, lutropin, chorion gonadotropin, menotropin), somatropine (somatropin), desmopressin, terlipressin, gonadorelin, triptorelin, leuprorelin, buserelin, nafarelin, and goserelin.
[0072] Examples of polysaccharides include glycosaminoglycans, hyaluronic acid, heparin, low molecular weight heparin or very low molecular weight heparin or their derivatives, or sulfated polysaccharides, such as the above-mentioned polysaccharides in polysulfated form, and / or their pharmaceutically acceptable salts.An example of a pharmaceutically acceptable salt of polysulfated low molecular weight heparin is enoxaparin sodium.An example of a hyaluronic acid derivative is Hylan G-F20 (Synvisc®), sodium hyaluronate.
[0073] The term "antibody" as used herein refers to an immunoglobulin molecule or an antigen-binding portion thereof. Examples of antigen-binding portions of an immunoglobulin molecule include F(ab) and F(ab')2 fragments that retain the ability to bind to an antigen. An antibody can be a polyclonal antibody, a monoclonal antibody, a recombinant antibody, a chimeric antibody, a deimmunized or humanized antibody, a fully human antibody, a non-human (e.g., murine) antibody, or a single chain antibody. In some embodiments, an antibody has effector function and is capable of fixing complement. In some embodiments, an antibody has reduced or no binding ability to Fc receptors. For example, an antibody can be an isotype or subtype, an antibody fragment, or a mutant that does not support binding to Fc receptors, e.g., with a mutation or deletion of the Fc receptor binding region. The term antibody also includes antigen-binding molecules based on tetravalent bispecific tandem immunoglobulins (TBTIs) and / or dual variable region antibody-like binding proteins (CODVs) with crossover binding region orientation.
[0074] The term "fragment" or "antibody fragment" refers to a polypeptide (e.g., antibody heavy and / or light chain polypeptide) derived from an antibody polypeptide molecule that does not include the full-length antibody polypeptide but includes at least a portion of the full-length antibody polypeptide that is still capable of binding to an antigen. An antibody fragment can include truncated portions of a full-length antibody polypeptide, but the term is not limited to such truncated fragments. Antibody fragments useful in the present invention include, for example, Fab fragments, F(ab')2 fragments, scFv (single-chain Fv) fragments, linear antibodies, monospecific or multispecific antibody fragments, such as bispecific, trispecific, tetraspecific and multispecific antibodies (e.g., diabodies, triabodies, tetrabodies), monovalent or multivalent antibody fragments, such as bivalent, trivalent, tetravalent and multivalent antibodies, minibodies, chelating recombinant antibodies, tribodies or bibodies, intrabodies, nanobodies, small modular immunopharmaceuticals (SMIPs), binding domain immunoglobulin fusion proteins, camelized antibodies, and VHH-containing antibodies. Additional examples of antigen-binding antibody fragments are known in the art.
[0075] The term "complementarity determining region" or "CDR" refers to short polypeptide sequences in the variable regions of both heavy and light chain polypeptides that are primarily responsible for mediating specific antigen recognition. The term "framework region" refers to amino acid sequences in the variable regions of both heavy and light chain polypeptides that are not CDR sequences and are primarily responsible for maintaining the proper arrangement of CDR sequences to allow antigen binding. Although framework regions themselves typically do not directly participate in antigen binding, as is known in the art, certain residues in the framework regions of a particular antibody may be directly involved in antigen binding or may affect the ability of one or more amino acids in the CDR to interact with an antigen.
[0076] Exemplary antibodies are anti-PCSK-9 mAbs (e.g., alirocumab), anti-IL-6 mAbs (e.g., sarilumab), and anti-IL-4 mAbs (e.g., dupilumab).
[0077] Pharmaceutically acceptable salts of any of the APIs described herein are contemplated for use in the drug or medicament in the drug delivery device. Pharmaceutically acceptable salts include, for example, acid addition salts and base salts.
[0078] Those skilled in the art will understand that modifications (addition and / or removal) of the various components of the APIs, formulations, devices, methods, systems, and embodiments described herein may be made without departing from the full scope and spirit of the present disclosure, which encompasses such modifications and all equivalents thereof.
[0079] In the following, a number of examples of a drug delivery device configured to interact with an auxiliary device, a drug delivery device, an auxiliary device and a drive unit of a drug delivery system are illustrated and described in more detail by referring to the drawings: [Brief description of the drawings]
[0080] [Figure 1] FIG. 1 is a block diagram of a drug delivery system. [Diagram 2] FIG. 1 shows a schematic diagram of an example of a drug delivery device realized as a hand-held pen-type injector. [Diagram 3] 1 is a cross-sectional view of an example of an auxiliary device configured to be attached to an injection device. [Figure 4] FIG. 13 shows the auxiliary device when attached to the injection device. [Diagram 5] FIG. 13 illustrates the interlocking mechanism of the auxiliary device when in a locking configuration. [Figure 6] FIG. 13 illustrates the interlocking mechanism of the auxiliary device when in a released configuration. [Figure 7] 13A-13D show further examples of interlocking mechanisms in a locking configuration. [Figure 8] FIG. 8 shows the example of FIG. 7 with the interlocking mechanism in an open configuration. [Figure 9] FIG. 13 is a cross-sectional view of an example of an interlocking mechanism in a locking configuration. [Figure 10] FIG. 10 is a cross-sectional view of the interlocking mechanism of FIG. 9 when in an open configuration. [Figure 11] FIG. 13 is a cross-sectional view of another example of an interlocking mechanism in a locking configuration. [Figure 12] FIG. 12 is a cross-sectional view of the interlocking mechanism of FIG. 11 when in an open configuration. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0081] 2 shows an exemplary embodiment of a drug delivery device 1. The drug delivery device 1 is a variable dose device in which different doses of the drug to be dispensed are set or dialed in respectively by the user. The drug delivery device is a dial expansion pen.
[0082] 1 also shows a coordinate system used herein to specify the location of members or elements or features. The distal direction D and the proximal direction P are parallel to the longitudinal axis A. The longitudinal axis A is the main axis of extension of the device 1. The radial direction R is perpendicular to and intersects the longitudinal axis A. The tangential direction, also called the circumferential direction, is perpendicular to the radial direction R and the longitudinal axis A.
[0083] The drug delivery device 1 includes a drive unit 3 having a setting mechanism and a dispensing mechanism. The setting mechanism is configured to set a drug dose and the dispensing mechanism is configured to dispense a drug dose. The functioning principle of each mechanism is further explained below.
[0084] The drug delivery device 1 further comprises a container unit 2 including a cartridge holder 15 configured and sized to receive a medicament container 16, for example in the form of a cartridge. The medicament container 16 is proximally sealed by a stopper 17. This particular drive unit 3 is merely illustrative of the wide variety of drive units and injection devices with which the presently described auxiliary device 100 can be used. Further details regarding specific implementations of the drive unit 3 can be found, for example, in WO 2004 / 078239 A1, WO 2004 / 078240 A1 or WO 2004 / 078241 A1, the entire contents of which are incorporated herein by reference.
[0085] The drive unit 3 includes a number sleeve 50 configured to move when the dose dial 12 is turned to provide a visual indication of the currently set dose. The dose dial 12 rotates a helical path relative to the housing 9 as it is rotated during setting and / or dispensing or expelling a dose. The housing 9 may include a window 8, for example in the form of an aperture through which a portion of the outer surface of the number sleeve 50 is visible.
[0086] The injection device 1 is configured to generate a mechanical click sound when the dose dial 12 is turned, providing acoustic feedback to the user. The number sleeve 50 mechanically interacts with a stopper 17 in the cartridge or medicament container 16. During delivery of a dose, the dose dial 12 rotates with an axial movement, i.e. without rotation, to its initial position, while the number sleeve 50 rotates back to its initial position, e.g. to indicate a dose of zero units. The injection device 1 can be realized as a disposable injection device. The cartridge holder 15 is sized and configured to accommodate the medicament container 16. The cartridge holder 15 is non-removably fastened by its proximal end to a proximal housing part 9, realized for example as a body of the drive unit 3. The cartridge holder 15 is covered by a protective cap 14, which is removably fastened to the cartridge holder 15 and / or the housing 9.
[0087] The housing 9 and / or an internal flange-like support includes a threaded axial through-hole that threadably engages with a first or distal thread of the piston rod 20. The distal end of the piston rod 20 includes a bearing in which a presser 23 is free to rotate about the longitudinal axis of the piston rod 20. The presser 23 is configured to axially abut against a proximally facing thrust bearing surface of the stopper 17 of the container 16. During a dosing operation, the piston rod 20 rotates relative to the housing 9, thereby imparting a distal forward movement relative to the housing.
[0088] The piston rod 20 is provided with a first thread 22 at or near its distal end and further with a second thread 24 at its proximal end. The first thread 22 and the second thread 24 are on opposite sides. A drive sleeve 30 is further provided having a hollow interior for receiving the piston rod 20. The drive sleeve 30 includes an internal thread for threadedly engaging the proximal thread of the piston rod 20. The drive sleeve 30 further includes an externally threaded section 31 at its distal end. The threaded section 31 is axially constrained between a distal flange portion 32 and another flange portion 33, i.e. a proximal flange portion 33 located at a predetermined axial distance from the distal flange portion 32. Between the two flange portions 32, 33 is provided a final dose limiter 35 in the form of a semicircular nut having an internal thread that fits into the threaded section 31 of the drive sleeve 30.
[0089] The final dose limiter 35 further includes a radial recess or protrusion on its outer periphery for engaging a complementary shaped recess or protrusion on the inside of the side wall of the housing 9. In this way, the final dose limiter 35 is splined to the housing 9. During successive dose setting procedures, rotation of the drive sleeve 30 in the dose increment or clockwise direction results in a cumulative axial displacement of the final dose limiter 35 relative to the drive sleeve 30.
[0090] There is further provided an annular spring 36 which axially abuts the proximally facing surface of flange portion 33. There is further provided a tubular clutch 40. A first end of clutch 40 is provided with a series of circumferentially oriented sawtooths. A radially inwardly facing flange is disposed toward a second, opposite end of clutch 40.
[0091] Further, a dose dial sleeve, also indicated as number sleeve 50, is provided. The number sleeve 50 is provided outside the spring 36 and the clutch 40 and is located radially inside the housing 9. A helical groove 51 is provided around the outer surface of the number sleeve 50. The housing 9 is provided with a dose window through which a portion of the outer surface of the number sleeve 50 can be seen. The housing 9 further comprises a helical rib 11 on the inner sidewall portion of the insert piece 10, which is adapted to seat in the helical groove 51 of the number sleeve 50. The tubular insert piece 10 is inserted into the proximal end of the housing 9. The insert piece 10 is non-rotatably and axially fixed in the housing 9. A first and a second stop are provided in the housing 9 to limit the dose setting procedure while the number sleeve 50 rotates in a helical motion relative to the housing 9.
[0092] A dose dial 12 in the form of a dose dial grip is disposed about the outer surface of the proximal end of the number sleeve 50. The outer diameter of the dose dial 12 typically corresponds to, coincides with and may form or be part of the outer diameter of the housing 9. The dose dial 12 is non-rotatably fixed to the number sleeve 50 to prevent relative movement therebetween. The dose dial 12 is provided with a central opening.
[0093] The trigger 13, also indicated as dose button, is substantially T-shaped. The trigger 13 is provided at the proximal end of the injection device 1. The trigger 13 may form or constitute the proximal end of the housing 9. The shaft 19 of the trigger 13 extends through an opening in the dose dial 12, through the inner diameter of the extension of the drive sleeve 30, and into a receiving recess in the proximal end of the piston rod 20. The shaft 19 is held against limited axial movement within and rotation relative to the drive sleeve 30. The head of the trigger 13 is generally circular. A trigger sidewall or skirt extends from the periphery of the head and is further adapted to seat in a proximally accessible annular recess of the dose dial 12.
[0094] To dial in the dose, the user rotates the dose dial 12. With the spring 36 and clutch 40 engaged, the drive sleeve 30, spring 36, clutch 40 and number sleeve 50 rotate together with the dose dial 12. Torque is transmitted through the sawtooth between the spring 36 and clutch 40. The helical groove 51 of the number sleeve 50 and the helical groove of the drive sleeve 30 have the same lead. This causes the number sleeve 50 to extend from the housing 9 and the drive sleeve 30 to lift the piston rod 20 at the same speed. At the limit of travel, the radial stop of the number sleeve 50 engages either the first stop or the second stop provided on the housing 9, preventing further movement in the first rotational sense, e.g. the dose increase direction. Rotation of the piston rod 20 is prevented by the fact that the entire driven thread on the piston rod 20 is in the opposite direction.
[0095] A final dose limiter 35 , which is keyed to the housing 9 , is advanced along the threaded section 31 by rotation of the drive sleeve 30 .
[0096] During dialing or setting of a dose, the ratchet mechanism permits and supports rotation of the number sleeve 50 relative to the clutch 40 along a second rotational sense, which rotation is accompanied by a regular click of the flexible arms of the clutch 40. Angular momentum applied to the number sleeve 50 along a first rotational sense is consistently transferred to the clutch 40, where the mutually corresponding ratchet configurations of the ratchet mechanism provide torque transfer from the number sleeve 50 to the clutch 40.
[0097] Once the desired dose has been dialed in, the user can dispense the set dose by simply depressing the trigger 13. This causes the clutch 40 to displace axially relative to the number sleeve 50, disengaging its dog teeth. However, the clutch 40 remains keyed for rotation relative to the drive sleeve 30. The number sleeve 50 and dose dial 12 are now free to rotate in accordance with the helical grooves 51.
[0098] The axial movement deforms the flexible arms of spring 36, ensuring that the sawtooth does not loosen during dispensing. This prevents drive sleeve 30 from rotating relative to housing 9, but is still free to move axially relative to housing 9. This deformation is then used to push spring 36 and clutch 40 back along drive sleeve 30, restoring the connection between clutch 40 and digit sleeve 50 when distally directed dosing pressure is removed from trigger 13.
[0099] Longitudinal axial movement of the drive sleeve 30 causes the piston rod 20 to rotate through an opening in the support of the housing 9, thereby advancing a stopper 17 in the container 16 and expelling a drug dose through an injection needle 18 attached to the distal end of the injection device. Once the dialed dose has been dispensed, the number sleeve 50 is prevented from further rotation by contact of at least one stop extending from the dose dial 12 with at least one corresponding stop on the housing 9. The zero dose position is determined by abutment of one of the axially extending edges or stops of the number sleeve 50 with at least one or several corresponding stops on the housing 9.
[0100] 3 to 6 there is shown diagrammatically an example of an auxiliary device 100 configured to be attached to the proximal end 5 of the drive unit 3. The auxiliary device 100 comprises a housing 101. The housing 101 comprises a first housing part 102 and a second housing part, e.g. in the form of a control element 104 movably arranged in the housing part 102.
[0101] The housing part 102 includes or forms a fastener 103 configured and shaped to be removably fastened to the proximal end of the drive unit 3. As shown in Figures 3 and 4, the fastener 103 is provided on an inner surface of the somewhat tubular shaped housing part 102. The housing part 102 forms or configures a receptacle 108 sized and shaped to engage with an outer surface of the dose dial 12.
[0102] Thus, the fasteners 103 may be configured and operable to form at least one of a form fit and a friction fit with the outer surface of the sidewall of the dose dial 12. The dose dial 12 may comprise longitudinal ribs that may support the non-rotatable engagement of the fasteners 103 to the dose dial 12, where the dose dial 12 represents a first component of the drug delivery device 1.
[0103] The control element 104, and thus the second housing part movably disposed in the housing part 102, includes a knob-like shape. The control element 104 includes an interior hollow space in which the electronic unit 70 is disposed. The control element 104 includes a receptacle sized and shaped to receive at least a portion of the housing part 102. As shown in more detail in FIG. 3, the housing part 102 includes a second tubular sidewall section 118 that engages with a respective first sidewall section 116 of the control element 104, where the sidewall section 116 is permanently fixed to or integral with the control element 104.
[0104] The second sidewall section 118 is in longitudinal sliding engagement with the first sidewall section 116. The first sidewall section 116 is provided to a carrier 106 that is rigidly fastened to the control element 104. The carrier 106 can surround a cup-shaped receptacle of the control element 104 in a distal direction D. The carrier 106 includes a distally facing surface 107 that effectively closes a receptacle 108 of the housing portion 102 in a proximal direction P.
[0105] The carrier 106 is configured to mechanically support an electronic unit 70. The electronic unit 70 includes a processor 72, a printed circuit board (PCB) 71, and a battery 73. The electronic unit 70 may optionally include a sensor 74, storage 75, a communication interface 76, a display 78, and a signal generator 79. The electronic unit 70 is operatively coupled to a locking mechanism 150 that includes an electromechanical actuator 151. More details about the electronic unit are provided below in connection with FIG. 1.
[0106] 4, a drug delivery system 200 is shown in which an auxiliary device 100 is removably fastened to a proximal end 5 of a drug delivery device 1. The drug delivery system 200 includes the auxiliary device 100 and the drug delivery device 1.
[0107] The auxiliary device 100 includes a locking mechanism 150 featuring an electromechanical actuator 151. The electromechanical actuator 151 is operable or controllable by the electronics unit 70 and thus the processor 72 of the electronics unit 70. The locking mechanism 150 is transitionable between a locked configuration, shown in Figure 5, and a released configuration, shown in Figure 6. In the locked configuration, the locking mechanism 150 is operable to prevent or inhibit longitudinal sliding movement of the control element 104 relative to the fastener 103.
[0108] Typically, to dispense a dose, it is necessary to apply a distal pushing force to the control element 104 to move it distally relative to the fastener 103. Because the fastener 103 is rigidly attached to the dose dial 12, each distal movement of the control element 104 induces the application of a distal force to the trigger 13 or trigger button, thereby serving to trigger or control the dispensing action of the drive unit 3.
[0109] As shown in more detail in Figures 5 and 6, the locking mechanism 150 comprises a locking element 152 mechanically coupled to an electromechanical actuator 151 by a piston 153. The piston 153, and thus the locking element 152, is movable by the electromechanical actuator 151 between a radially recessed or retracted position, shown in Figure 6, and a radially extended position, shown in Figure 5. When in the extended position, shown in Figure 5, the locking element 152 is located within a free space 110 that is confined in a distal direction by an end face 111 of the second sidewall section 118, and further confined in a proximal direction by a stop face 112 of the carrier 106, and thus by the control element 104.
[0110] The longitudinal size of the blocking element 152 substantially matches the longitudinal extent of the free space 110. In this manner, the electromechanical actuator is in a locking position or blocking configuration when the locking element 152 is in the radially extended position. The presence of the locking element 152 in the free space 110, or in the recess formed between the faces 111, 112, inhibits and prevents distal movement of the carrier 106, and thus the control element 104, relative to the fastener 103.
[0111] Thus, if the user must apply a dosing force in a distal direction to the control element 104, such dosing force cannot operate to induce movement of the control element 104 relative to the fastener 103. Thus, the user cannot depress the trigger 13 in the distal direction D. Only upon transition of the electromechanical actuator 151 to the released position shown in FIG. 6 does the locking element 152 get removed from the free space 110 between the end face 111 and the stop face 112.
[0112] The control element 104 and its carrier 106 are then no longer hindered from moving distally when a user applies respective distal pressure to the control element 104. Thus, the first sidewall section 116, and thus the control element 104, is permitted to slide longitudinally along the second sidewall section 118 of the fastener 103.
[0113] Distal-facing surface 107 of carrier 106 is then operable to apply a respective distal pressure to trigger 13 effective to depress the trigger to dispense a dose.
[0114] In another example, it is contemplated that the inwardly facing surface of the second sidewall section 118 defines a recess, for example a radial recess, shaped and configured to engage the locking element 152. When the locking element 152 is in the locking position, the control element 104 is prevented from moving away from its idle position shown in FIG. 5. When the locking element 152 retracts from the respective radial recess of the second sidewall section 118, the first and second sidewall sections 116, 118, respectively, are disengaged, thus allowing the control element 104 to be moved to an actuated position displaced distally from the idle position.
[0115] In Figures 7 to 12 two further examples of auxiliary devices 100 are shown with different kinds of locking mechanisms 250. All other parts of the auxiliary device 100 according to Figures 7 to 12 are realized in the same way as described above in connection with Figures 3 to 6.
[0116] The locking mechanism 250 also includes an electromechanical actuator 251. However, this actuator 251 is mechanically coupled to an axis 253 extending along a longitudinal direction A. The axis 253 functions as a longitudinal shaft and is coupled to a locking disk 255. The locking disk 255 is rotatable relative to the axis 253 through actuation of the electromechanical actuator 251. Here, the electromechanical actuator 251 is implemented as a stepper motor and is thus operable to rotate the locking disk 255 relative to the axis 253.
[0117] As shown in Figures 7 and 8, both of which represent the idle position of the fastener 103, the locking element 252, and in particular the locking disk 255, is located longitudinally offset from the second sidewall section 118 of the fastener 103. A distally facing surface of the locking element 252, and thus the locking disk 255, may axially abut the proximal end surface 111 of the second sidewall section 118. As shown, for example, in Figures 9 and 10, the locking disk 255 is elliptical in shape. Thus, the locking disk 255 may include two opposing longitudinal ends 254 located at a radial distance greater than the inner diameter of the tubular second sidewall section 118.
[0118] 7 and 9, opposing longitudinal ends 254 are offset from complementary longitudinal slots 120, 121 diametrically opposed in the inner surface of second sidewall section 118. In this configuration, the geometry and orientation of locking disk 255 does not match the interior or geometry of second sidewall section 118, thereby preventing longitudinal insertion of locking disk 255, and thus locking element 252, into the free space circumferentially confined by second sidewall section 118.
[0119] Activation of the electromechanical actuator 251 may serve to rotate the locking element 252 about the axis 253. When the released position shown in Figures 8 and 10 is reached, the longitudinal ends 254 on either side of the oval shaped locking disk 255 may be aligned with the slots 120, 121. The inner distance of the sidewall section 118 in the area between the two slots 120, 121 is equal to or slightly greater than the outer distance between the longitudinal end sections 254 on either side of the locking disk 255.
[0120] This configuration allows the locking disk 255 to move longitudinally into the interior space of the second sidewall section 118. Thus, the keyed structure of the locking element 252 is properly aligned with the corresponding keyed structure of the second sidewall section 118 to permit and support longitudinal and distal sliding movement of the locking element 252, and thus longitudinal displacement of each of the first sidewall sections 116 of the control element 104 relative to the second sidewall section 118 of the fastener 103.
[0121] In the further example of Figures 11 and 12, the locking disc 255 is provided with a keyed structure 256 on its outer periphery. The keyed structure 256 includes a number of recesses 264 and protrusions 265. When viewed along the circumference of the locking disc 255, the recesses 264 and corresponding protrusions 265 are arranged in an alternating manner. The inner surface of the second sidewall section 118 is provided with a complementary shaped corresponding keyed structure 126. The corresponding keyed structure 126 also includes a number of radially inwardly projecting protrusions or teeth 124 and recesses 125 arranged in an alternating manner on or along the inner circumference of the second sidewall section 118.
[0122] 11, the projections 265 of the keyed structure 256 are aligned with the projections or teeth 124 of the corresponding keyed structure 126. In this misaligned alignment or configuration, the keyed structure 256 is in blocking engagement with the corresponding keyed structure 126. By rotating the locking disk 255 through actuation of the electromechanical actuator 251 about the axis 253, the projections 265 of the keyed structure 256 are aligned with the recesses 125 of the corresponding keyed structure 126.
[0123] Thus, the teeth 124 of the corresponding keyed structure 126 are aligned with the recesses 264 of the keyed structure 256. Similarly, with this type of matching keyed alignment of the keyed structure 256 with the corresponding keyed structure 126, the locking mechanism 250 is in a released configuration and the control element 104 is displaceable longitudinally, e.g., distally, relative to the fastener 103 to trigger a dose dispensing or dose injection operation.
[0124] FIG. 1 is a schematic block diagram of a drug delivery system 200 including a drug delivery device 1 and with an auxiliary device 100 .
[0125] The auxiliary device 100 comprises in particular a printed circuit board (PCB) 71. The PCB is provided with a processor 72. The processor 72 may be, for example, a microprocessor, a digital signal processor (DSP), an application specific integrated circuit (ASIC), a field programmable gate array (FPGA), etc. The processor 72 is configured and operable to execute program code (e.g. software or firmware) stored in a storage 75. The storage 75 may include a program memory or may use a main memory for example to store intermediate results. The storage 75 may also be used to store a logbook regarding the ejections / injections performed. The storage 75, and thus the program memory, may be, for example, a read-only memory (ROM) and the main memory may be, for example, a random access memory (RAM).
[0126] In some examples, the processor 72 interacts with an input in the form of one or more buttons or actuators, for example, that turn the auxiliary device 100 on and off. A further button can be implemented as a communication button. This further button can be used to trigger the establishment of a communication link or data connection to the external electronic device 80, for example, implemented as a smartphone. Yet another button can be implemented as a confirmation or OK button. This button can be used to confirm information presented to a user of the auxiliary device 100. The button can be any suitable form of user input transducer, such as, for example, a mechanical switch, a capacitive sensor, or other touch sensor.
[0127] The processor 72 may control a display 78 or display unit, currently embodied as a liquid crystal display (LCD). The optional display 78 is operable to display, for example, the current settings of the injection device 1 or information regarding the next injection to be performed to a user of the auxiliary device 100. The display 78 or display unit may also be embodied as a touch screen display, for example, to receive user input.
[0128] The processor 72 may further be operatively coupled to a sensor 74. The sensor 74 may be implemented as an optical sensor embodied as an optical character recognition (OCR) reader that may capture an image of the window 12 or the dose display in which the currently selected dose is displayed (according to numbers printed on a sleeve 26 included in the injection device 1, which numbers are visible through the window 12 or the dose display). The OCR reader may further recognize characters (e.g. numbers) from the captured image and provide this information to the processor 72.
[0129] Alternatively, the sensor 74 of the auxiliary device 100 may simply be an optical sensor, such as a camera, for capturing an image and providing information about the captured image to the processor 72. The processor 72 may then be operable to perform OCR on the captured image.
[0130] The processor 72 may also control a light source, such as a light emitting diode, to illuminate the window 12 in which the currently selected dose is displayed. A diffuser, for example made from a piece of acrylic glass, may be used in front of the light source. Additionally, the light sensor 74 may include a lens (e.g., an aspheric lens) that provides a magnification (e.g., a magnification of greater than 3:1).
[0131] The sensor 74 may also be implemented as an acoustic sensor, which is configured to sense sounds generated by the injection device 1. Such sounds may occur, for example, when a dose is dialed in by turning the dose dial 12 or dose button 13, and / or when a dose is ejected / injected by the dose button 13 or trigger 13, and / or when a prime shot is performed. These actions are mechanically similar, but nevertheless have different sounds (which may even be electronic sounds indicating these actions). Here, either the sensor 74 and / or the processor 72 may be configured to distinguish between these different sounds, for example, so that it can be safely recognized that an injection has been performed (and not just a prime shot).
[0132] The processor 72 may further control a signal generator 79, implemented for example as an acoustic signal generator configured to generate an acoustic signal that may be related, for example, to an operating state of the injection device 1, for example, as feedback to the user. For example, an acoustic signal is emitted by the signal generator 79 as a reminder of the next dose to be injected or as a warning signal, for example in case of misuse. The acoustic signal generator may be embodied, for example, as a buzzer or a speaker. In addition to or instead of the acoustic signal generator 79, a tactile signal generator (not shown) may also be used to provide tactile feedback, for example by vibration.
[0133] The processor 72 further controls a communication interface 76, implemented for example as a radio unit or radio transceiver. The communication interface 76 is configured to transmit and / or receive information to and from another device in a wireless manner. Such transmission can be based for example on radio or optical transmission. Typically, the communication interface 76 is implemented according to a commercially available wireless communication standard such as Bluetooth, Wi-Fi, UWB, or NFC.
[0134] Alternatively, the communication interface 76 may include a wired unit configured to transmit and / or receive information to and from another device in a wired manner, for example via a cable or fiber connection. When data is transmitted, the units of the transmitted data (values) can be explicitly or implicitly defined. For example, for insulin doses, International Units (IU) are always used, otherwise the units used are explicitly transferred, for example in coded form.
[0135] The processor 72 may be operable to receive input from a pen detection switch (not shown), which is operable to detect whether the pen 1 or drug delivery is present, i.e., whether the auxiliary device 100 is properly coupled to the injection device 1. A battery 73 provides power to the processor 72 and other components of the electronic unit 70.
[0136] Thus, the auxiliary device 100 can determine information related to the status and / or use of the injection device 1. This information can be displayed on the display 21 for use by a user of the device. This information is either processed by the auxiliary device 100 itself or at least partly provided to an external electronic device 80 for further data processing.
[0137] Generally, information regarding the size of the dose currently set, dialed or dispensed is obtained by the sensor 74 and stored in the local storage 75. Data repeatedly captured or acquired during repeated and subsequent uses of the injection device 1 may be stored in the storage 75. Such injection-related data stored in the storage 75 may be synchronized, for example, by the communication interface 76 communicating with an external electronic device 80 and / or with an external database 96, for example hosted or provided by a healthcare provider.
[0138] Typically, the external electronic device 80 is realized as a smartphone, a smart watch, or a tablet computer. The external electronic device 80 may also include a wide area communication interface 88 for establishing a communication link with an external database 92 via a communication network 90. Typically, the external electronic device 80 is a mobile device or a wearable device. The external electronic device 80 includes a display 81 and / or a speaker 82 for interacting with a user.
[0139] The external electronic device 80 can be wirelessly paired with the electronic unit 70. When the pairing is successful, a respective confirmation is provided to the user, e.g. via a display 81 and / or via a speaker 82 of the external electronic device 80. When data or information is transferred between the electronic unit 70 and the external electronic device 80, a visual and / or audible confirmation is provided to the user, e.g. by the electronic unit 70 and / or by the external electronic device 80.
[0140] The processor 72 is configured to perform automatic relocking, for example, after the end of each dosing or injection procedure. Furthermore, based on the signal obtained from the sensor 74, the processor 72 is provided with information indicative of the remaining fill level of the medicament container 16. In this manner, when the sensor 74 provides a respective sensor signal that the medicament container 16 is substantially depleted or empty, the processor 72 can control and / or actuate the release mechanism 250, 350, and thus the actuator 251, 351, to transition the mechanical locking element 51, 151 to the locked position.
[0141] In a further example, the electrically controlled release mechanism 250, 350 of the auxiliary device 100 is controlled by the processor 72 based on an authentication routine implemented by the auxiliary device 100 and / or implemented by an external electronic device. This may be particularly applicable to reusable injection devices 1 having a common drive unit 3 but differentiated by the container unit 2 and / or by the medicament stored in the medicament container 16.
[0142] Here, a particular container unit 2 with a medicament container 16 is visually or electronically coded by a respective coding feature, implemented for example as a barcode, as a QR code or in the form of an electronically readable code, for example provided by an RFID chip. At least one of the auxiliary device 100 and the external electronic device 80 may be operable to capture and / or read or extract the coding feature of the container unit 2. Based on the captured coding feature, the processor 72 may be operable to activate or deactivate the locking mechanism 150, 250. In the unlikely event that an incorrect container unit 2 is paired and / or coupled with the drive unit 3, the coding feature captured and / or processed by the processor 72 cannot operate to activate the interlock mechanism 150, 250 for switching the mechanical locking element 152, 252 to the release position. The locking mechanism 50, 150 can then remain in the locking position or locking configuration. Misuse or unintended use of the drive unit 3 is effectively prevented.
[0143] The electronic unit 70, in particular its processor 72, may be operable to activate the interlocking mechanism 150, 250 only if a correct coding feature is detected. The evaluation of the correct coding feature is performed by the processor 72 and / or by a processor of the external electronic device 80. Here, approval of the authentication to unlock the locking mechanism 150, 250 is also performed by the external electronic device 80. [Explanation of symbols]
[0144] 1. Drug Delivery Devices 2 Container unit 3 Drive unit 4 Distal end 5 Proximal end 8. Windows 9 Drive unit housing 10 Insert 11 Spiral rib 12 Dose Dial 13 Trigger 14 Protective cap 15 Cartridge holder 16 Drug containers 17 Stopper 18 Syringe needle 19 Shaft 20 Piston rod 21 Bearing part 22 1st thread 23 Press 24 Second Thread 30 Drive sleeve 31 Threaded Section 32 Flange 33 Flange 35 Final Dose Limiter 36 Spring 40 Clutch 50 Number Sleeve 51 Groove 70 Electronic Unit 71 Printed Circuit Board 72 processors 73 Battery 74 Sensors 75 Storage 76 Communication Interface 78 Display 79 Signal Generator 100 Auxiliary Devices 101 Housing 102 Housing part 103 Fasteners 104 Control Elements 106 Career 107 Surface 108 Receptacle 110 Free Space 111 End face 112 Stop surface 116 Sidewall Section 118 Sidewall Section 120 Slots 121 Slots 124 teeth 125 Recess 126 Keyed Structure 150 Locking mechanism 151 Actuator 152 Locking Elements 153 Piston 200 Drug Delivery Systems 250 Locking mechanism 251 Actuator 252 Locking Elements 253 Axis 254 End Section 255 Locking Disk 256 Keyed Structure 264 Recess 265 Protrusion
Claims
1. An auxiliary device (100) for attachment to a drug delivery device (1), the drug delivery device operable to set and dispense a drug dose, the auxiliary device (100) comprising: a fastener (103) configured to fasten to the first component (12) of the drug delivery device (1); a control element (104) configured to engage a second component (13) of the drug delivery device (1) and movable relative to the fastener (103) to guide movement of the second component (13) relative to the first component (12) when the fastener (103) is attached to the first component (12); an electronic unit (70) including a processor (72); a locking mechanism (150; 250) controllable by a processor (72) and including an electromechanical actuator (151; 251) operable to block or inhibit movement of the control element (104) relative to the fastener (103); The auxiliary device.
2. 2. The auxiliary device (100) of claim 1, wherein the control element (104) is movable relative to the fastener (103) along the longitudinal direction (A) between an idle position and an activated position.
3. 3. The auxiliary device (100) of claim 1 or 2, wherein the control element (104) includes a first sidewall section (116) and the fastener (103) includes a second sidewall section (118), the first sidewall section (116) being in longitudinal sliding engagement with the second sidewall section (118).
4. The auxiliary device (100) of any one of claims 1 to 3, wherein the locking element (150; 250) comprises a locking element (152; 252) mechanically coupled to an electromechanical actuator (151; 251) and is movable between a locked position and a released position by the electromechanical actuator (151; 251).
5. 5. The auxiliary device (100) of claim 4, wherein the locking element (152; 252) is movably disposed on one of the fastener (103) and the control element (104) and is mechanically engagable with the other of the fastener (103) and the control element (104) when in a locking position.
6. 6. The auxiliary device (100) according to claim 4 or 5, wherein the locking element (152; 252) is movable along a radial or lateral direction between a locking position and a release position.
7. The auxiliary device (100) according to any one of claims 3 and 4 to 6, wherein the locking element (152; 252) projects radially from one of the first sidewall section (116) and the second sidewall section (118) and is configured to engage with a radial recess or a longitudinal end face (111) of the other of the first sidewall section (116) and the second sidewall section (118).
8. The auxiliary device (100) according to any one of claims 4 to 7, wherein the locking mechanism (152) is mechanically coupled to the electromechanical actuator (151) by a moveable piston (153).
9. The auxiliary device (100) according to any one of claims 4 to 8, wherein the locking element (252) is rotatable or pivotable about an axis (253) extending along the longitudinal direction.
10. The auxiliary device (100) according to any one of claims 4 to 9, wherein the locking element (152; 252) comprises a locking disc (255) having a keyed formation (256) extending around the circumference of the locking disc (255).
11. 11. The auxiliary device (100) of claim 10, wherein the locking element (252) is disposed on one of the control element (104) and the fastener (103), and the other of the control element (104) and the fastener (103) includes a receptacle (108) having a corresponding keyed structure (126) of a shape complementary to the keyed structure (256).
12. 12. The auxiliary device (100) of claim 2 and any one of claims 10 or 11, wherein the locking disc (255) is positioned longitudinally offset from the corresponding keyed structure (126) when the control element (104) is in the idle position, the locking disc (255) being operable to prevent longitudinal movement of the control element (104) relative to the fastener (103) to the activation position when the keyed structure (256) is offset relative to the corresponding keyed structure (126).
13. The auxiliary device (100) of any one of claims 2 and 10 to 12, wherein the control element (104) is movable relative to the fastener (103) towards the activated position only when the keyed structure (256) of the locking disk (255) is aligned with a corresponding keyed structure (126) of the receptacle (108).
14. An auxiliary device (100) as claimed in any one of claims 1 to 13, wherein the drug delivery device (1) comprises a dose dial (12) for setting a dose and a trigger (13) for dispensing the dose, the dose dial (12) and the trigger (13) being provided as separate components movable relative to each other, the fastener (103) being configured to fix or fasten to the dose dial (12), and the control element (104) being operable to mechanically engage with the trigger (13).
15. An auxiliary device (100) as claimed in any one of claims 1 to 14, wherein the control element (104) is displaceable longitudinally relative to the fastener (103) to guide a drug delivery operation when the auxiliary device (100) is attached to the dose dial (12) of the drug delivery device (1).
16. 1. A drug delivery system comprising: A drug delivery device (1) for setting and dispensing a drug dose, said drug delivery device (1) comprising: a container unit (2) configured to accommodate a drug container (16); a drive unit (3) operably engageable with a medication container (16) for setting and dispensing a medication dose; at least one of a dose dial (12) for setting a dose, and a trigger (13) for dispensing the dose; The drug delivery system further comprises:
16. The drug delivery system comprising an auxiliary device (100) according to any one of claims 1 to 15, wherein the fastener (103) is configured to be fixed to one of the dose dial (12) and the trigger (13).
17. 17. The drug delivery system (200) of claim 16, wherein the fastener (103) is configured to be fixed or fastened to the dose dial (12) and the control element (104) is operable to mechanically engage with the trigger (13).
18. The drug delivery system according to claim 16 or 17, wherein the drug delivery device (100) further comprises a drug container (16) arranged in the container unit (2).
Citation Information
Patent Citations
Drug injection device with lockout function
JP2013507159A
drug delivery device
JP2018506401A
Data acquisition device attached to injection device
JP2018517502A
Devices and methods for accurate dose delivery
JP2021506372A
